MetaCap

Who Owns Celldex Therapeutics Stock?

NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

27.42-0.54 (-1.93%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Ownership breakdown

Held by institutions
114.42%
Institutional holders
335
  • Institutions 99.7%
  • Insiders 0.3%
  • Public and other 0.0%

Who owns Celldex Therapeutics stock?

Institutional investors own about 114.4% of Celldex Therapeutics's shares, spread across 335 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.27% of CLDX.

The largest institutional holders are Wellington Management Group, LLP (13.58%), FMR, LLC (10.99%) and Blackrock Inc. (8.84%). Together, the top 10 institutions control 62.9% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their CLDX positions and 5 reduced them.

Summary generated from market data by MetaCap's automated system. Methodology

Top institutional holders of CLDX

Celldex Therapeutics top institutional holders
InstitutionShares% HeldChange
Wellington Management Group, LLP10.67M13.58%+11.8%
FMR, LLC8.64M10.99%+132.0%
Blackrock Inc.6.95M8.84%-0.8%
Kynam Capital Management, LP5.07M6.45%-4.8%
Price (T.Rowe) Associates Inc4.39M5.58%-6.4%
State Street Corporation3.48M4.43%-10.8%
Vanguard Capital Management LLC3.48M4.42%+0.3%
Baker Bros. Advisors, LP2.56M3.26%+116.9%
Deep Track Capital, Lp2.13M2.71%-27.7%
Geode Capital Management, LLC2.05M2.61%+1.3%

% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.

Top mutual fund and ETF holders of CLDX

Celldex Therapeutics top fund holders
FundShares% Held
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund3.78M4.82%
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.49M3.17%
iShares Trust-iShares Russell 2000 ETF2.02M2.57%
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.60M2.04%
Vanguard Explorer Fund1.45M1.84%
T. Rowe Price New Horizons Fund, Inc.1.25M1.60%
MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund1.04M1.32%
T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U.970.81K1.24%
Fidelity Select Portfolios-Select Biotechnology Portfolio951.17K1.21%
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund897.53K1.14%

Frequently asked questions

Who is the largest shareholder of Celldex Therapeutics?

Wellington Management Group, LLP is the largest institutional shareholder of CLDX, owning 13.58% of shares outstanding (10.67M shares) as of its latest 13F filing.

What percentage of Celldex Therapeutics is owned by institutions?

Institutions own about 114.4% of CLDX shares and 114.7% of the public float.

How much of Celldex Therapeutics do insiders own?

Insiders, such as officers and directors, own about 0.27% of CLDX shares outstanding.

Where does institutional ownership data come from?

Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.

Related